| Autor: |
Suller Marti, AS, Mirsattari, SM, MacDougall, KW, Steven, D, Parrent, A, Andrade, A, de Ribaupierre, S, Diosy, DC, McLachlan, R, Burneo, JG |
| Zdroj: |
The Canadian Journal of Neurological Sciences; November 2021, Vol. 48 Issue: Supplement 3 pS15-S15, 1p |
| Abstrakt: |
Background:For patients with generalized epilepsy who do not respond to anti-seizure medications, the therapeutic options are limited. Vagus nerve stimulation (VNS) is a treatment mainly approved for therapy resistant focal epilepsy. There is limited information on the use of VNS on generalized epilepsies, including Lennox Gastaut Syndrome(LGS) and genetic generalized epilepsy(GGE). Methods:We identified patients with a diagnosis of Lennox-Gastaut Syndrome or Genetic Generalized Epilepsy, who underwent VNS implantation, between1997 and July 2018. Results:A total of 46 patients were included in this study with a history of therapy resistant generalized epilepsy. The mean age at implantation was 24 years(IQR= 17.8-31 years) and 50%(n=23) were female. The most common etiologies were GGE in 37%(n=17) and LGS in 63%(n=29). Median follow-up since VNS implantation was 63 months(IQR:31-112.8months). 41.7%(n=12) of the LGS group became responders, and 64.7%(n=11) in the GGE group. The best response in seizure reduction was seen in generalized tonic-clonic seizures. There was a reduction of seizure-related hospital admissions from 89.7%(N=26) pre-implantation, to 41.4%(N=12) post-implantation (p<0.0001). The frequency of side effects due to the stimulation was similar in both groups(62.1% in LGS and 61.1% in GGE). Conclusions:VNS is an effective treatment in patients with therapy resistant generalized epilepsy, especially GGE. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
